Five things for pharma marketers to know: Monday, February 5

Share this content:

Bristol-Myers Squibb's Opdivo hits key goal in late-stage trial. The drug, in combination with Yervoy, was shown to improve progression-free survival in patients with advanced lung cancer. The company's stock was up on the news on Monday morning, while rival Merck's dipped slightly. (CNBC)

The government of the Philippines has sued Sanofi over its anti-dengue vaccine. The lawsuit is seeking compensation for the parents of a 10-year-old girl who, according to health officials in the country, died after receiving the shot. In November, Sanofi said the vaccine could increase the risk of severe dengue in people not previously exposed to the virus. (Reuters)

As U.S. flu season worsens, hospitals reach capacity. Flu hospitalization rates are the highest they've ever been since the Centers for Disease Control and Prevention started tracking the metric in 2005. In Allentown, Pennsylvania, an overburdened hospital set up a “surge tent” to handle the influx of cases. (The New York Times)

New government research on cell phone radiation isn't conclusive. The study, which took more than a decade to complete, found that high levels of radiation from phones were linked to tumors in male rats, but not in female rats or mice. The FDA said it had “not found sufficient evidence that there are adverse health effects in humans caused by exposures at or under the current radio-frequency exposure limits.” (Consumer Reports)

President Donald Trump has criticized Democrats for pushing universal healthcare coverage. On Twitter, Trump referenced the funding problems faced by the British single-payer healthcare system. He tweeted that thousands of U.K. citizens are marching in protest. (Axios)

Share this content:
Scroll down to see the next article